Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

摘要: Patients with immune-mediated inflammatory diseases (IMIDs) may have impaired initial humoral responses after SARS-CoV-2 vaccination depending on the type of immunosuppression (ISP) used. 1 It is largely unknown how antibody titres develop over time and whether it is needed to adjust timing of booster campaigns for patients with IMID. This is a study on long-term persistence of seroconversion after vaccination in patients with IMID on ISP, patients with IMID not on ISP and healthy controls. This study is part of an ongoing national prospective multicentre cohort study in the Netherlands (Target-to-B! study; trial ID NL8900). Participants were included from 2 February 2021 and 1 October 2021. Participants with seroconversion (ie,> 4 AU/mL) after primary immunisation with either BNT162b2 or CX-024414 in whom serum samples were collected 28 days after primary immunisation and before the first additional …